佛罗里达州 的 多发性骨髓瘤 临床试验
佛罗里达州 有 54 项针对 多发性骨髓瘤 的研究正在招募参与者。
佛罗里达州 的城市
- Miami22 项研究
- Jacksonville19 项研究
- Tampa15 项研究
- Kendall7 项研究
- Deerfield Beach6 项研究
- Hollywood6 项研究
- Plantation5 项研究
- Coral Springs5 项研究
- Fort Lauderdale3 项研究
- Pembroke Pines3 项研究
官方研究文本（英文）
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables
- University of Miami Hospital and Clinics - Deerfield Beach, Deerfield Beach
- Sylvester Comprehensive Cancer Center- Doral, Doral
- 以及另外 12 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT06152575At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
- Mayo Clinic in Florida, Jacksonville
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月6日 · NCT05969860A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Moffitt Cancer Center, Tampa
招募中4 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT05201781A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Memorial Healthcare System, Hollywood
- AdventHealth Medical Group Blood & Marrow Transplant at Orlando, Orlando
- Cleveland Clinic Florida, Weston
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Florida Cancer Specialists & Research Institute, Fort Myers
- Mayo Clinic Jacksonville, Jacksonville
- University of Miami Hospital, Miami
- 以及另外 1 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Memorial Healthcare System, Hollywood
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT04634552A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Mayo Clinic - Florida, Jacksonville
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月30日 · NCT07284758A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- University of Miami, Miami
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月30日 · NCT07280013A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Baptist MD Anderson Cancer Center, Jacksonville
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月29日 · NCT06615479Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- Comprehensive Hematology Oncology, St. Petersburg
招募中4 期
18 岁及以上 · 所有性别 · 更新于 2026年10月27日 · NCT07609940A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables
- Sylvester Comprehensive Cancer Center - Coral Springs, Coral Springs
- University of Miami Hospital and Clinics Deerfield Beach, Deerfield Beach
- 以及另外 8 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月27日 · NCT05623020Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Florida, Jacksonville
- Moffitt Cancer Center, Tampa
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月27日 · NCT06465316Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Moffitt Cancer Center - McKinley Drive, Tampa
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月26日 · NCT03761108A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Miami, Miami
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月26日 · NCT04973605A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Mayo Clinic Hospital - Florida, Jacksonville
- University of Miami Don Soffer Clinical Research Center, Miami
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月22日 · NCT05651932A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Jacksonville
- Research Site, Tampa
招募中3 期
18 至 130 岁 · 所有性别 · 更新于 2026年10月21日 · NCT07735637A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Moffitt Cancer Center /ID# 279068, Tampa
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月20日 · NCT07409246A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Moffitt Cancer Center /ID# 272628, Tampa
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月19日 · NCT06892522A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Tampa
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月15日 · NCT07681596Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- SSAK Partners, Coral Springs
- Mayo Clinic - Jacksonville, Jacksonville
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月14日 · NCT07648264AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Jacksonville
- Research Site, Miami
- Research Site, Tampa
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月8日 · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Florida, Jacksonville
- Miami Cancer Institute at Baptist Health, Inc., Miami
- Moffitt Cancer Center, Tampa
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月6日 · NCT06297226A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 102, St. Petersburg
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT07582432Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
- Mayo Clinic in Florida, Jacksonville
招募中
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT06630104The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- Mayo Clinic in Florida, Jacksonville
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月30日 · NCT07285044A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Tampa
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Jacksonville, Jacksonville
- Memorial Cancer Institute, Pembroke Pines
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07518186A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Cancer Specialists of North Florida, Jacksonville
- D&H National Research Center, Margate
- Ocala Oncology Center, Ocala
- 以及另外 2 项
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT07477587TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Miami/Sylvester Cancer Institute - Aventura, Aventura
- University of Miami/Sylvester Cancer Institute - Lennar, Coral Gables
- University of Miami/Sylvester Cancer Institute - Deerfield Beach, Deerfield Beach
- 以及另外 8 项
招募中2 期
12 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT02693535ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
- University of Miami, Miami
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月21日 · NCT06997081Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Florida, Jacksonville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年8月28日 · NCT06375044A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Moffitt Cancer Center, Tampa
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年8月28日 · NCT07075185A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Fort Myers
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月25日 · NCT07227311A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Sylvester Comprehensive Cancer Center - Aventura, Aventura
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center, Coral Gables
- Sylvester Comprehensive Cancer Center - Coral Springs, Coral Springs
- 以及另外 6 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年8月24日 · NCT05020236Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Holy Cross Hospital, Fort Lauderdale
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年8月19日 · NCT04566328A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Pembroke Pines
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月19日 · NCT05714839IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
- University of Miami, Miami
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月18日 · NCT06376526Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Coral Gables
- Research Site, Tampa
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年8月14日 · NCT07764978A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Mayo Clinic in Florida, Jacksonville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年7月16日 · NCT06121843Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
- Mayo Clinic in Florida, Jacksonville
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年7月14日 · NCT05847569数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。